Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity. A Prospective Randomized Placebo-controlled Study

NCT03878433 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nice as lead sponsor.

NCT NCT03878433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03878433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity. A Prospective Randomized Placebo-controlled Study
Lead sponsor
Centre Hospitalier Universitaire de Nice
Phase
Not applicable
Overall status
Completed
Start date
April 1, 2019
Completion date
July 1, 2020
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melasma